These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 35654363

  • 1. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
    Lally DR, Hill L, Amador-Patarroyo MJ.
    Ophthalmol Retina; 2022 Nov; 6(11):1054-1060. PubMed ID: 35654363
    [Abstract] [Full Text] [Related]

  • 2. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
    Holekamp NM, Sadda S, Sarraf D, Guymer R, Hill L, Blotner S, Spicer G, Gune S.
    Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
    [Abstract] [Full Text] [Related]

  • 3. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
    Khurana RN, Chang L, Day BM, Ghanekar A, Stoilov I.
    Ophthalmol Retina; 2020 Aug; 4(8):760-766. PubMed ID: 32387055
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.
    Zarbin MA, Hill L, Maunz A, Gliem M, Stoilov I.
    Br J Ophthalmol; 2022 Nov; 106(11):1561-1566. PubMed ID: 34039560
    [Abstract] [Full Text] [Related]

  • 6. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, López Gálvez MI, Arias Barquet L, Figueroa MS, García-Arumí J, García-Layana A, In-Eye Study Group.
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [Abstract] [Full Text] [Related]

  • 7. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, FLUID Investigators.
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [Abstract] [Full Text] [Related]

  • 8. Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.
    Sadda S, Holekamp NM, Sarraf D, Ebraheem A, Fan W, Hill L, Blotner S, Spicer G, Gune S.
    Graefes Arch Clin Exp Ophthalmol; 2022 Dec; 260(12):3781-3789. PubMed ID: 35687173
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
    Fung AT, Kumar N, Vance SK, Slakter JS, Klancnik JM, Spaide RS, Freund KB.
    Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
    [Abstract] [Full Text] [Related]

  • 17. Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.
    Staurenghi G, Cozzi M, Sadda S, Hill L, Gune S.
    Ophthalmol Retina; 2023 Apr; 7(4):300-306. PubMed ID: 36372347
    [Abstract] [Full Text] [Related]

  • 18. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y, Miller DM, Fung AE, Hill LF, Rosenfeld PJ.
    Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
    [Abstract] [Full Text] [Related]

  • 19. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, Lu C, Katz TA, Schmidt-Erfurth U.
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [Abstract] [Full Text] [Related]

  • 20. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.